



NICU Clinical Controversies and Pearls



Authors:

Nishant Srinivasan, MD

*Assistant Professor of Clinical Pediatrics,
Associate Program Director, Neonatal-Perinatal Fellowship
Director of Simulation, Department of Pediatrics,
Children's Hospital at the University of Illinois (CHUI)*

and



Jennifer T. Pham, PharmD, BCPS, BCPPS

*Clinical Pharmacist, Neonatal Intensive Care Unit
University of Illinois Hospital and Health Sciences System
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy*

and



Holly D. Maples, PharmD

*Associate Professor, Dept of Pharmacy Practice
Jeff and Kathy Lewis Sanders College of Pharmacy Endowed Chair in Pediatrics
Director, Pediatric Infectious Diseases and Antimicrobial Stewardship Fellowship Program
Director, Arkansas Children's Antimicrobial Stewardship Program*

Disclosure(s): Dr. Srinivasan, Dr. Pham, Dr. Maples, and the reviewers who contributed to this activity have no relevant financial relationships of interest to disclose.

Purpose: To educate healthcare providers on neuroprotective effects of erythropoiesis-stimulating agents (ESAs) and its potential role in neurodevelopment in preterm and term neonates. To educate health care providers about the risks and benefits of high-dose caffeine citrate in premature infants. To educate health care providers on the importance of practicing antimicrobial stewardship in the neonatal population.

Learning Objectives:

Upon completion of this activity, participants should be able to:

- Explain findings from pre-clinical and clinical studies for potential benefits of ESAs on neurodevelopmental outcomes in preterm infants.
- Describe the use of ESAs in term infants and specific conditions in which ESAs may promote improved neurodevelopmental outcomes.
- Discuss the clinical studies on the risks and benefits of high-dose caffeine citrate in preterm infants
- Recognize the impact of antimicrobial duration on a neonates gut microbiome.
- Identify common uses of antimicrobials in neonates and assess the opportunities to improve duration of treatment.

Target Audience: Physicians, Physician Assistants, and Nurse Practitioners

Type of Activity: Knowledge-based

Fee: \$10 (or \$45 for all 10 courses). For C4 2021 participants who registered for the live program, please use the access code provided to you by email.

Release and Most Recent Review Date: September 24, 2021

Expiration Date: August 28, 2022

Estimated time to complete activity: 1.0 hour CME (1.0 AMA PRA Category 1 Credit)

Location: Please visit <https://medicinece.uic.edu/> to participate in this activity.

Continuing Medical Education Statement:



The University of Illinois College of Medicine at Chicago is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Illinois College of Medicine at Chicago designates this Enduring Material CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Earn Credit:

Participants must complete the activity as described above in the Continuing Medical Education Statement by viewing the entire presentation video and completing a post-test and activity evaluation. A certificate of completion will be issued after all requirements as described are completed.

Hardware/Software and Internet Requirements can be found at <https://medicinece.uic.edu/>

Provider Contact Information: For general information please call the Office of Continuing Education and Meeting Services toll-free at (866) PHARM-CE (866-742-7623) or send an e-mail to: pharmce@uic.edu. Copyright © 2021 – The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. [Privacy Policy](#).